[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333187-105":59,"doc-detail-333187-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-incremental-healthcare-cost-associated-with-cancer-in-belgium-a-registry-based-data-analysis","The incremental healthcare cost associated with cancer in Belgium - A registry-based data analysis","","Belgium saw a rapid rise in cancer diagnoses, motivating an estimate of the annual healthcare burden by cancer site and a comparison of costs with disease-burden measures. The study used nationally available data with a prevalence-based approach for 10-year prevalent cases in 2018, calculating attributable expenditure by matching patients with cancer to controls without cancer, and summarizing health impact using YLD. Results highlighted the largest per-patient costs for bronchus and lung cancer and the highest total spending for lung cancer. Conclusions support evidence for cost-containment policies and prevention via risk-factor reduction.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-incremental-healthcare-cost-associated-with-cancer-in-belgium-a-registry-based-data-analysis/333187/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-incremental-healthcare-cost-associated-with-cancer-in-belgium-a-registry-based-data-analysis/333187.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main aim in Belgium?","Question",{"text":112,"@type":113},"To estimate the annual incremental healthcare costs associated with cancer by site and compare cost results with disease-burden estimates for better understanding of the impact of different cancer sites.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were healthcare expenditures and health impact measured?",{"text":117,"@type":113},"Healthcare expenditure was estimated using a prevalence-based approach for 10-year prevalent cancer cases in 2018, using matching of cancer patients by site with controls. Health impact was summarized using years of life lost due to disability (YLD).",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancer sites generated the highest costs in 2018?",{"text":121,"@type":113},"Bronchus and lung cancer had the highest average attributable cost per patient (€15,867). For total cost, lung cancer was the most costly site with almost €700 million spent, followed by breast and colorectal cancer with costs over €300 million each.",{"name":123,"@type":110,"acceptedAnswer":124},"What prevention and policy direction does the study suggest?",{"text":125,"@type":113},"Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors, and the findings are intended to guide cost containment policies.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},333187,1790802399,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","DOI: 10. 1002/cam4 .6659  \nRESEAR CH ARTICLE  \nThe incremental healthcare cost associated with cancer in Belgium: A registry-based data analysis  \nVanessa Gorasso1,2  | Stefanie Vandevijvere1 | Johan Van der Heyden1 | Ingrid Pelgrims3,4 | Henk Hilderink5 | Wilma Nusselder6 | Claire Demoury3 | Masja Schmidt1 | Stijn Vansteelandt4 | Delphine De Smedt2 |  \nBrecht Devleesschauwer1,7  \n1Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium  \n2Department of Public Health and Primary Care, Ghent University, Ghent, Belgium  \n3Department of Risk and Health Impact Assessment, Sciensano, Brussels, Belgium  \n4Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium  \n5Centre for Public Health Forecasting, National Institute for Public Health and the Environment (RIVM), Utrecht, The Netherlands  \n6Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands  \n7Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium  \nCorrespondence  \nVanessa Gorasso, Health Information, Department of Epidemiology and Public Health, Sciensano, Rue J Wytsman 14, Brussels 1050, Belgium. [Email:](Email: vanessa.gorasso@sciensano.be)[ vanessa.gorasso@sciensano.be](Email: vanessa.gorasso@sciensano.be)  \nAbstract  \nBackground: Similar to many countries, Belgium experienced a rapid increase in cancer diagnoses in the last years. Considering that a large part of cancer types could be prevented, our study aimed to estimate the annual healthcare burden of cancer per site, and to compare cost with burden of disease estimates to have a better understanding of the impact of different cancer sites in Belgium.  \nMethods: We used nationally available data sources to estimate the healthcare expenditure. We opted for a prevalence-based approach which measures the disease attributable costs that occur concurrently for 10-year prevalent cancer cases in 2018. Average attributable costs of cancer were computed via matching of cases (patients with cancer by site) and controls (patients without cancer) . Years of life lost due to disability (YLD) were used to summarize the health impact of the selected cancers.  \nResults: The highest attributable cost in 2018 among the selected cancers was on average €15,867 per patient for bronchus and lung cancer, followed by liver cancer, pancreatic cancer, and mesothelioma. For the total cost, lung cancer was the most costly cancer site with almost €700 million spent in 2018. Lung cancer was followed by breast and colorectal cancer that costed more than €300 million each in 2018.  \nConclusions: In our study, the direct attributable cost of the most prevalent cancer sites in Belgium was estimated to provide useful guidance for cost containment policies. Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors.  \nKEYWORDS  \nburden of disease, cancer, cost-of-illness  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine. 2024;13:e6659 .  \n[https://doi.org/10.1002/cam4.6659](https://doi.org/10.1002/cam4.6659)  \n[wileyonlinelibrary.com/journal/cam4](wileyonlinelibrary.com/journal/cam4)  \n1 of 9  \n1 | INTRODUCTION  \nSimilar to many countries in the world, Belgium experienced a rapid increase in cancer diagnoses in the last years. In 2019, 80,524 persons were diagnosed with cancer and a total of 432,106 people had a cancer diagnosis in the previous 10 years.1 The increase in cancer incidence is largely attributed to population growth, the aging population, and increased exposure to risk factors (e.g. overweight and obesity, tobacco, exposure to human papillomavirus or hepatitis B or hepatitis C viruses) resulting in ","cbCaicgmRp6PkBLH","https://ap.wps.com/l/cbCaicgmRp6PkBLH","pdf",772105,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Study rationale and context\n## Cost-of-illness study design considerations\n## Need for registry-based national data","[{\"question\":\"What was the study’s main aim in Belgium?\",\"answer\":\"To estimate the annual incremental healthcare costs associated with cancer by site and compare cost results with disease-burden estimates for better understanding of the impact of different cancer sites.\"},{\"question\":\"How were healthcare expenditures and health impact measured?\",\"answer\":\"Healthcare expenditure was estimated using a prevalence-based approach for 10-year prevalent cancer cases in 2018, using matching of cancer patients by site with controls. Health impact was summarized using years of life lost due to disability (YLD).\"},{\"question\":\"Which cancer sites generated the highest costs in 2018?\",\"answer\":\"Bronchus and lung cancer had the highest average attributable cost per patient (€15,867). For total cost, lung cancer was the most costly site with almost €700 million spent, followed by breast and colorectal cancer with costs over €300 million each.\"},{\"question\":\"What prevention and policy direction does the study suggest?\",\"answer\":\"Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors, and the findings are intended to guide cost containment policies.\"}]","The incremental healthcare cost associated with cancer in Belgium - A registry-based data analysis | PDF",1790001339,23]